2023-11-23 15:52
STOCKHOLM (Nyhetsbyrån Direkt) The research company Lipigon announces that the lipid-lowering drug candidate Lipisense reduced the concentration of the target protein ANGPTL4 in the blood of healthy subjects with statistically significant significance.
This is stated in a press release.
The reduction in blood plasma amounted to 29 percent compared to the placebo group.
“We previously reported a reduction in the target protein ANGPTL4, and we are pleased to report that this now constitutes a statistically significant reduction. Additionally, we see indications of a pronounced treatment effect for the higher dose levels, although a statistically significant reduction has not yet been reached . Since the completed phase I study is first and foremost a safety study, the statistical basis required to be able to differentiate the treatment groups is still missing,” comments CEO Stefan K. Nilsson.
“The results give hope for an effect on cardiometabolic diseases such as type 2 diabetes and cardiovascular diseases,” the press release states.
Stock exchange editorial offices +46 8 51917911
News agency Direkt
2023-11-23 15:08:07
#SIGNIFICANT #REDUCTION #TARGET #PROTEIN #LIPISENSE
